

# Robert B Belshe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7631695/publications.pdf>

Version: 2024-02-01

29  
papers

1,739  
citations

471509

17  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

2558  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutralizing Antibody Kinetics and Immune Protection Against Herpes Simplex Virus 1 Genital Disease in Vaccinated Women. <i>Journal of Infectious Diseases</i> , 2023, 227, 522-527.	4.0	7
2	Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 226, 1489-1498.	4.0	10
3	Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older Adults. <i>Journal of Immunology</i> , 2020, 204, 1661-1673.	0.8	28
4	Molecular analyses and phylogeny of the herpes simplex virus 2 US9 and glycoproteins gE/gI obtained from infected subjects during the Herpevac Trial for Women. <i>PLoS ONE</i> , 2019, 14, e0212877.	2.5	2
5	Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. <i>PLoS ONE</i> , 2019, 14, e0214467.	2.5	4
6	The Potential of Live, Attenuated Influenza Vaccine for the Prevention of Influenza in Children. <i>Clinical Infectious Diseases</i> , 2019, 69, 795-796.	5.8	5
7	Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses. <i>Science Immunology</i> , 2017, 2, .	11.9	122
8	Molecular Evolution of Herpes Simplex Virus 2 Complete Genomes: Comparison between Primary and Recurrent Infections. <i>Journal of Virology</i> , 2017, 91, .	3.4	22
9	The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects. <i>PLoS ONE</i> , 2017, 12, e0176687.	2.5	5
10	Development of a high-throughput $\hat{I}^2$ -Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples. <i>Vaccine</i> , 2016, 34, 3901-3906.	3.8	7
11	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. <i>Vaccine</i> , 2016, 34, 547-554.	3.8	4
12	Prolonged Proinflammatory Cytokine Production in Monocytes Modulated by Interleukin 10 After Influenza Vaccination in Older Adults. <i>Journal of Infectious Diseases</i> , 2015, 211, 1174-1184.	4.0	62
13	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	3.8	92
14	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. <i>Vaccine</i> , 2015, 33, 163-173.	3.8	3
15	Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses. <i>PLoS ONE</i> , 2015, 10, e0144738.	2.5	7
16	Aging-dependent alterations in gene expression and a mitochondrial signature of responsiveness to human influenza vaccination. <i>Aging</i> , 2015, 7, 38-52.	3.1	72
17	Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women. <i>Journal of Infectious Diseases</i> , 2014, 209, 828-836.	4.0	94
18	Repertoire of Epitopes Recognized by Serum IgG from Humans Vaccinated with Herpes Simplex Virus 2 Glycoprotein D. <i>Journal of Virology</i> , 2014, 88, 7786-7795.	3.4	31

#	ARTICLE	IF	CITATIONS
19	Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1420.	7.4	45
20	Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization. Journal of Virology, 2014, 88, 14278-14288.	3.4	60
21	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant. Journal of Infectious Diseases, 2011, 203, 666-673.	4.0	56
22	Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response. Journal of Immunology, 2010, 184, 2518-2527.	0.8	472
23	The need for quadrivalent vaccine against seasonal influenza. Vaccine, 2010, 28, D45-D53.	3.8	168
24	Evaluation of smallpox vaccines using variola neutralization. Journal of General Virology, 2009, 90, 1962-1966.	2.9	44
25	Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults. Journal of Infectious Diseases, 2007, 195, 1590-1597.	4.0	152
26	Safety, Efficacy, and Effectiveness of Live, Attenuated, Cold-Adapted Influenza Vaccine in an Indicated Population Aged 5-49 Years. Clinical Infectious Diseases, 2004, 39, 920-927.	5.8	98
27	Dose-Dependent Neutralizing Antibody Responses to Vaccinia. Journal of Infectious Diseases, 2004, 189, 493-497.	4.0	33
28	HIV Type 1 Vaccine-Induced T Cell Memory and Cytotoxic T Lymphocyte Responses in HIV Type 1-Uninfected Volunteers. AIDS Research and Human Retroviruses, 2001, 17, 1175-1189.	1.1	24
29	Influenza Prevention and Treatment: Current Practices and New Horizons. Annals of Internal Medicine, 1999, 131, 621.	3.9	10